Expanding Access Through the TAVI Roadshow
One of the highlights of 2024 was our TAVI Roadshow, which spanned multiple cities across India. This initiative brought together cardiologists, healthcare professionals, and patients, creating a platform to demonstrate the effectiveness of the Vienna Aortic Valve SE therapy, in addressing a diverse range of anatomical challenges offering a minimally invasive solution for patients with severe aortic stenosis.
Pioneering TricValve Therapies Globally
Our TricValve therapy continued to make significant inroads in 2024, addressing the unmet needs of patients with tricuspid regurgitation. Notable milestones included successful procedures in India & elsewhere, where patients experienced life-changing improvements in their quality of life. These achievements were further amplified by impactful presentations at global platforms such as International Conferences, Exhibitions & Symposiums in Hospitals, where renowned Cardiologists presented the effectiveness of our devices.
Global Collaboration and Knowledge Sharing
The year 2024 was also defined by robust global collaborations. At many conferences, we engaged with industry leaders, physicians, and business partners, sharing insights on our cutting-edge technologies. Our active participation in these events reinforced our position as a trusted partner in the medical device industry, driving innovation and excellence in manufacturing.
State-of-the-Art Manufacturing and New Product Launches
Our state-of-the-art integrated manufacturing facility has been a cornerstone of our success, enabling us to produce high-quality medical devices that meet global standards.
This year, we marked significant milestones with new product launches across coronary, peripheral, and structural heart divisions, reaffirming our commitment to innovation in cardiovascular care and further enhance treatment options for patients with complex cardiovascular conditions. From advanced stent technologies to life-transforming therapies, our portfolio continues to address critical patient needs. These launches signify our dedication to providing cutting-edge solutions that improve outcomes and redefine possibilities in modern healthcare.
Improving Patient Lives and Outcomes
At Relisys Medical Devices, improving patient lives and outcomes remains at the core of everything we do. Through innovative therapies like the TricValve® and Vienna Aortic Valve SE®, we’ve transformed complex cardiac conditions into treatable possibilities, offering new hope to patients worldwide. By combining cutting-edge technology, collaboration with healthcare professionals, and a commitment to excellence, we continue to enhance the quality of life for those who need it the most.
Building Scientific Evidence for our Devices through Clinical Studies
We made significant strides in building scientific evidence for our devices through rigorous clinical studies and registries.
- We have successfully completed the enrolment & follow-up of >1000 patients for the post-marketing surveillance study that we have undertaken with our premium drug-eluting stent, PRISTINE+. This study has provided real-world insights into our device performance, safety & efficacy which is nothing less than the best. The Pristine+ Registry has been a forerunner for building scientific evidence for our devices.
- Post-market clinical Follow-up (PMCF) studies on our advanced balloons and catheters have reaffirmed their exceptional safety and reliability.
- The TRIO2 Study has been commenced marking an era in the scientific compilation of the safety and efficacy of TRICVALVE®, Transcatheter Bicaval Valves System in the Indian population with Tricuspid Regurgitation.
- Ongoing VIVA GLOBAL & VIVA INDIA Studies are evaluating the safety and efficacy of the Vienna Aortic Valve SE, a Transcatheter self-expandable Aortic Valve System in the Indian population with severe Aortic Stenosis.
These initiatives reflect our unwavering commitment to advancing evidence-based cardiovascular care and our commitment to HUMAN LIFE.
Looking Ahead
As we end 2024 successfully, we extend our gratitude to all our partners, collaborators, and healthcare professionals for their unwavering support. With a focus on expanding access to life-saving therapies, strengthening global collaborations, and investing in cutting-edge research and development, we are poised to make 2025 even more remarkable.
Wishing everyone a Healthy and Prosperous New Year 2025!